European Commission Approved its First JAK Inhibitor to Treat Atopic Dermatitis

The company ‘AbbVie’ announced that, the European Commission has approved RINVOQ, an oral, selective and reversible JAK inhibitor, used for the treatment of the moderate to severe atopic dermatitis in the adolescents of 12 years and above and adults, who have been the candidate for the systematic therapy of the disease.

According to the company, the recommended dose of the RINVOQ for the treatment of atopic dermatitis in the adult people is 15 mg or 30 mg, which is given once in a day based on the presentation of the individual patient, and 15 mg for the adolescents, and the RINVOQ can also be given with or without the TCS (topical corticosteroids).

Michael Severino, vice chairman, managing director and president of AbbVie said, this has been a significant milestone for the company in their pursuit of transforming the care in the atopic dermatitis patients, and they are very excited for providing an additional option for the treatment across the region of Europe and also helping to alleviate the burden of the unrelenting rash and itch, which many of the patients have been struggling with in their day to day life despite of the available options of the treatment.

The approval from the European commission has been supported by the data from one of the biggest registered Phase 3 programs in the treatment of atopic dermatitis along with more than 2,500 adolescents and adults suffering with the moderate to severe disease, and these studies have also evaluated the safety and efficacy of the RINVOQ monotherapy.